NUREXONE BIOLOGIC INC. Total Liabilities

Latest as of December 2025: €1.32 Million EUR ≈ $1.55 Million USD

NUREXONE BIOLOGIC INC. total liabilities. Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) has total liabilities worth €1.32 Million EUR (≈ $1.55 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NUREXONE BIOLOGIC INC. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Total Liabilities of NUREXONE BIOLOGIC INC. (2021–2025)

Total liabilities of NUREXONE BIOLOGIC INC. from 2021 to 2025. This chart illustrates how NUREXONE BIOLOGIC INC.'s total liabilities have evolved over time, based on quarterly financial data.

NUREXONE BIOLOGIC INC. Competitors by Total Liabilities

The table below lists competitors of NUREXONE BIOLOGIC INC. ranked by their total liabilities.

Company	Country	Total Liabilities
Sun Race Sturmey-Archer Inc TW:1526	Taiwan	NT$960.72 Million
Nureca Limited NSE:NURECA	India	Rs259.46 Million
Ege Seramik Sanayi ve Ticaret AS IS:EGSER	Turkey	TL4.75 Billion
Commerce Resources Corp. V:CCE	Canada	CA$2.58 Million
Italy Innovazioni SpA PA:MLITN	France	€919.76K
Autech Corporation KQ:067170	Korea	₩482.93 Billion
KCP Sugar and Industries Corporation Limited NSE:KCPSUGIND	India	Rs-4.60 Billion
Blue Star Helium Ltd AU:BNL	Australia	AU$32.72 Million

Liability Composition Analysis (2021–2025)

This chart breaks down NUREXONE BIOLOGIC INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of NUREXONE BIOLOGIC INC..

Liquidity & Leverage Metrics

NUREXONE BIOLOGIC INC. Total Liabilities Ratios Explained

NUREXONE BIOLOGIC INC. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	2.63	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.48	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NUREXONE BIOLOGIC INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NUREXONE BIOLOGIC INC. (2021–2025)

The table below shows the annual total liabilities of NUREXONE BIOLOGIC INC. from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€1.32 Million ≈ $1.55 Million	+94.85%
2024-12-31	€680.00K ≈ $794.99K	-65.67%
2023-12-31	€1.98 Million ≈ $2.32 Million	+183.81%
2022-12-31	€698.00K ≈ $816.04K	-57.93%
2021-12-31	€1.66 Million ≈ $1.94 Million	--

About NUREXONE BIOLOGIC INC.

F:J90 Germany Biotechnology

Market Cap

$30.78 Million

€26.33 Million EUR

Market Cap Rank

#23485 Global

#2051 in Germany

Share Price

€0.29

Change (1 day)

-2.72%

52-Week Range

€0.24 - €0.47

All Time High

€0.88